Biote Corp. Class A (BTMD)
NASDAQ: BTMDHealthcareMedical Care FacilitiesUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
BTMD stock chart
Technical analysisKey statistics
All statistics- Market cap
- $39.66M
- P/E (TTM)
- 8.36
- Forward P/E
- 2.60
- EPS (TTM)
- $0.14
- Dividend yield
- None
- 52-week range
- 1.06 – 3.26
- Day range
- 1.07 – 1.17
- Volume / Avg
- 147.20K / 230.14K
- Beta
- —
- Shares outstanding
- 28.68M
- Next earnings
- Nov 4, 2026
52-week range
BTMD stock today
Biote (BTMD) closed at $1.17 on Oct 8, up 5.41% (+$0.06), versus the S&P 500's 0.47% decline. Shares are 64.1% below their 52-week high of $3.26, set on Oct 22, 2025 and 10.4% above the 52-week low of $1.06, near the bottom of the past year's range. BTMD is down 55.0% year to date, underperforming the S&P 500 (+13.5%). Over the past 12 months, the stock has lost 59.2%.
Biote trades at 8.4x its trailing twelve-month earnings per share of $0.14. Its forward P/E of 2.6x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year. Biote's next earnings report is expected on Nov 4, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Biote
Company profilebiote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance.
- Sector
- Healthcare
- Industry
- Medical Care Facilities
- CEO
- Mr. Robert C. Peterson
- Headquarters
- Irving, TX
- Employees
- 223
- Website
- biote.com
Analyst forecast
ForecastConsensus (5 analysts)
none
Avg. price target
$2.61+123.08%
- Strong buy 0
- Buy 4
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 4, 2026
- EPS estimate
- $-0.05
Biote peers
Healthcare sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| CCELCryo-Cell International Inc. | 4.17 | +6.65% | $33.62M | vs BTMD |
| DCGODocGo Inc. | 0.3387 | -1.83% | $33.53M | vs BTMD |
| CCMConcord Medical Services Holdings Limited ADR | 3.10 | -0.80% | $13.46M | vs BTMD |
| AMSAmerican Shared Hospital Services | 1.33 | -1.48% | $8.84M | vs BTMD |
| BMGLBasel Medical Group Ltd | 3.60 | +9.76% | $5.70M | vs BTMD |
| NIVFNewGenIvf Group Limited Class A | 0.0811 | -23.49% | $2.21M | vs BTMD |
| PARKPark Dental Partners Inc. | 20.60 | -1.62% | $97.96M | vs BTMD |
| JYNTThe Joint Corp. | 7.12 | -1.11% | $100.70M | vs BTMD |
Indexes, lists and sector
Appears in lists
Biote stock FAQ
What is Biote's stock price today?
BTMD last traded at $1.17 as of Oct 8, 4:00 PM EDT, up 5.41% on the day. Prices are delayed at least 15 minutes.
When is Biote's next earnings date?
Biote is expected to report earnings on Wednesday, November 4, 2026. Analysts expect EPS of $-0.05.
What is BTMD's P/E ratio?
BTMD trades at a trailing P/E ratio of 8.36 and a forward P/E of 2.60.
Who is Biote's CEO?
Mr. Robert C. Peterson is the chief executive officer of Biote Corp. Class A, which has about 223 employees.
What is the BTMD 52-week high?
The 52-week high for BTMD is $3.26 and the 52-week low is $1.06. The stock is currently 64.1% below its high.